H1 20: soft guidance takes centre stage
14/08/20 -"Novozymes reported largely in line Q2 20 numbers as sales were down 2% (in line with the trading update) and the EBIT margin came in at 25.9% (-10bp vs trading update). The key takeaway was the ..."
Pages
55
Language
English
Published on
14/08/20
You may also be interested by these reports :
29/10/26
The Q3 EBITDA was somewhat ahead of expectations, unlike sales. While lower demand in Spain and loss of exclusivity in Japan impaired Bilastine’s ...
29/10/26
After increasing both our DCF and NAV estimates by >20% (discussed in the respective sections), we maintain a Reduce recommendation with c.2% ...
28/10/26
The Q3 profitability exceeded expectations, though sales came in line with consensus. The strong showing in ‘Specialty medicines’ made up for the ...
28/10/26
The Q3 sales missed consensus because of near-term biosimilar supply constraints, pricing pressure in Germany and lower prices for penicillin APIs – ...